题 目：Lighting Up Diseases with Dark Materials 报告人：Prof. Zhen Cheng (程震) School of Medicine, Stanford University Email ：zcheng@stanford.edu 时 间：2015年11月1日（星期天）上午10：30 地 点：仙林校区化学楼H-201 摘要：A variety of molecular platforms including small molecules, peptides, aptamers and nanoparticles have been explored for molecular imaging of diseases. Melanin is a natural dark pigment that can be found in most organisms, and it has been extensively studied as a biomarker for melanotic melanoma. Molecular probes that can bind to melanin or are involved in the melanin biosynthesis pathway have been pursued for melanin targeted imaging. Over the past decade, we have developed clinical translatable 18F, 99mTc labeled benzamide analogs for melanin targeted PET and SPECT imaging. Furthermore, because of its’ strong chelation ability of metal ions and light absorption property, melanin can serve as an excellent target for multimodality imaging of diseases including PET, MRI and photoacoustic imaging (PAI). Tyrosinase, the key enzyme regulating melanin production, was thus explored as a novel reporter gene for PET/MRI/PAI trimodality imaging. Importantly, melanin nanoparticles have also been developed and used as new nanoplatforms for multimodality imaging and theranostics. Lastly, besides melanin, several other dark materials including perylene-3,4,9,10-tetracarboxylic diiimide-based near-infrared-absorptive organic nanoparticles have been studied as new multimodal nanoplatforms for biomedical applications. 报告人简介：Dr. Zhen Cheng is an Associate Professor of Radiology and a member of the Molecular Imaging Program at Stanford (MIPS), BioX program, Canary Center at Stanford for Cancer Early Detection and Stanford Cancer Center. He currently leads the Cancer Molecular Imaging Chemistry Laboratory of the MIPS where he is developing novel molecular probes, non-invasive imaging techniques and bionanotechnology for the multimodality early detection of cancer. Dr. Cheng is the President of Chinese American Society of Nuclear Medicine and Molecular Imaging, and he was the Board Director of the Radiopharmaceutical Sciences Council in the Society of Nuclear Medicine and Molecular Imaging. He has served as an active reviewer for numerous funding agencies and over 100 research journals such as Nature Nanotechnology, Nature Communications, Science Translational Medicine, JACS, Angewandte Chemie, JNM, etc., abstract reviewer and session chair for numerous meetings (SNM, WMIC, etc.). Moreover, he is Associate Editor of Frontiers in Biomedical Physics and Regional Editor of Current Molecular Imaging and sits on the editorial board of numerous peer-reviewed journals including Clinical Cancer Research. 太阳集团tcy8722 |